Business Wire

Pyramid Analytics Ascends to the Large / Enterprise-Wide Implementations Category in BARC BI & Analytics 22 Report

Share

Pyramid Analytics announced today that BARC (Business Application Research Center), a leading European analyst firm, elevated Pyramid’s Decision Intelligence Platform to the Large/Enterprise-Wide Implementations category. Pyramid received 40 Top Rankings (1st place) and 87 Leading Positions (place top 22-33% or top 2 products in its 6 peer groups) in The BI & Analytics Survey 22. Based on a sample of 2,478 survey responses, the BARC report offers an unsurpassed level of user feedback on 30 leading business intelligence (BI) solutions. BARC is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence and analytics (ABI).

Key Points:

  • 100 percent of customers surveyed would recommend Pyramid Analytics.
  • 97 percent of users rate Pyramid’s functionality for creating dashboards as excellent or good, beating the average rating by 82 percent.
  • 91 percent of users rate Pyramid Analytics’ vendor support as excellent or good. This is in sharp contrast with just 65 percent for the average BI tool.
  • 88 percent of users rate Pyramid Analytics’ price to value as excellent or good;notably higher than the 71 percent for average tools.
  • Downloadthe complimentary report.

BARC Net Assessment

“It has been another great year for Pyramid Analytics, scoring 40 top ranks and 87 leading positions across its six peer groups. Pyramid performed especially well in comparison to its rivals in the Large/Enterprise-Wide Implementations peer group, where half of its top ranks came,” the report’s authors wrote, adding that “Pyramid customers clearly benefit from using the software. We asked customers to rate their level of achievement of 11 different business benefits. Pyramid scored well above average in almost all these benefits. Compared to other vendors in the survey, Pyramid customers are especially likely to be able to reduce costs, improve customer satisfaction, and improve operational efficiency.”

BARC determined that the Pyramid Analytics Decision Intelligence Platform deployments, use cases, functionality, and performance met its requirements for Enterprise-Wide Implementations; is well-suited to support a broad range of BI and analytics use cases and large numbers of end-users in multiple roles; and is capable of managing Big Data without compromising critical factors such as query response time, flexible self-service, and ease of use.

Complete, Integrated Decision Intelligence

Only Pyramid’s Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use disparate, multiple tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, and industry-leading user adoption means faster time to value.

The Pyramid Analytics Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps from Original Equipment Manufacturers (OEM) and Independent Software Vendors (ISV) or delivered through Managed Services Providers (MSP).

Voice of the Customer

  • “A powerful platform with an abundance of well-thought out, integrated features and functionality. Fast, modern and sophisticated without being complicated.” Head of BI & Analytics Competence Center, Retail Industry, >2,500 employees
  • “A polished product supported by an enthusiastic and knowledgeable team.” CIO, Energy Industry, >2,500 employees
  • “A great product. Flexible and excellent self-service [BI & Analytics].” BI/Analytics Leader, Manufacturing Industry, >2,500 employees

Quotes

  • Carsten Bange, Founder and CEO, BARC: “If you are considering buying a BI product, you really need to know how other users and organizations rate it. The BI & Analytics Survey 22 captures what end users really think about the BI products they use. Input from Pyramid Analytics customers and our own assessment of its ABI platform revealed continued innovation. Pyramid Analytics is a growing vendor with an increasing presence in the market. Its product is highly competitive, as the results in The BI & Analytics Survey 22 show. It is therefore unsurprising to see it has a high win rate when competing for new deals. I am eager to watch their progress over the next year.”
  • Omri Kohl, CEO & Co-Founder, Pyramid Analytics: “We place tremendous value on The BI & Analytics Survey because BARC provides a painstakingly thorough analysis and, importantly, draws from real-world, hands-on experience. I thank Carsten and his team for their diligent research. And I am proud that the Pyramid Analytics Decision Intelligence Platform is again top-ranked or in a leadership position in all categories that mean the most to enterprise customers.”

Download a complimentary copy of Pyramid highlights in The BI & Analytics Survey 22 from BARC now.

About The BI & Analytics Survey 22

The BI & Analytics Survey 22 was conducted by BARC from March to June 2021. Altogether, 2,487 respondents worldwide answered a series of questions about their BI and analytics software. The survey offers a comparison of 30 leading business intelligence tools across 36 key performance indicators including Business Value, Customer Satisfaction, Customer Experience and Competitiveness. For more information, go to www.bi-survey.com.

About Pyramid Analytics

The Decision Intelligence Platform from Pyramid Analytics enables enterprises in any industry to maximize the value of data by unifying Data Preparation, Business Analytics, and Data Science in a single Analytics and Business Intelligence (ABI) infrastructure. By balancing performance and ease of use, everyone from business users to the most advanced data scientists get real-time, direct self-service access to reliable data from any domain or source, customized reports, and clear, actionable analysis. Flexible deployment options include on-premises and multi-cloud and hybrid environments. Schedule a demo.

Pyramid Analytics has offices in global innovation and business centers, including Amsterdam, London, New York City (US HQ), and Tel-Aviv, Israel. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.

The Pyramid Decision Intelligence Platform. Know What’s Next.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Chas Kielt
Vice President of Corporate Communications | Product and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye